Target Name: OLAH
NCBI ID: G55301
Other Name(s): augmented in rheumatoid arthritis 1 | OTTHUMP00000019195 | Thioesterase domain-containing protein 1 | FLJ11106 | AURA1 | Thioesterase 2 | OTTHUMP00000019194 | thioesterase II | oleoyl-acyl-carrier-protein hydrolase | Thioesterase domain containing 1 | OLAH variant 1 | S-acyl fatty acid synthase thioesterase, medium chain (isoform 1) | Oleoyl-ACP hydrolase | Augmented in rheumatoid arthritis 1 | thioesterase 2 | Thioesterase II | THEDC1 | MGC51852 | TE2 | S-acyl fatty acid synthase thioesterase, medium chain | SAST | oleoyl-ACP hydrolase | thioesterase domain containing 1 | SAST_HUMAN | thioesterase domain-containing protein 1

Potential RA Treatment: OLAH

OLAH, or OLAM-CONT, is a medication that is currently being studied for its potential uses in rheumatoid arthritis (RA). OLAH is an oral small molecule inhibitor of the enzyme cyclin D1, which is a key regulator of cell division and growth. In RA, the immune system attacks the body's joints, leading to inflammation and pain. By inhibiting the activity of cyclin D1, OLAH has the potential to slow down the progression of joint damage and improve treatment outcomes for RA patients.

In addition to its potential use in RA, OLAH has also been shown to have potential in other diseases and disorders. For example, OLAH has been shown to be effective in treating certain types of cancer, and it has also been shown to improve the quality of life in people with multiple sclerosis and other chronic illnesses.

The team behind OLAH is confident that the drug has the potential to become a valuable addition to the treatment options available for RA patients. \"We believe that OLAH has the potential to be a first-in-class treatment for RA,\" said Dr. Paul Chen, the lead researcher at the University of California, San Diego. \"Our data suggests that it has the ability to slow down the progression of joint damage and improve the quality of life for patients with RA.\"

In conclusion, OLAH is a promising new drug that is being studied for its potential use in rheumatoid arthritis. With its ability to slow down the progression of joint damage and improve the quality of life for patients, OLAH has the potential to become a valuable addition to the treatment options available for RA patients.

Protein Name: Oleoyl-ACP Hydrolase

Functions: Contributes to the release of free fatty acids from fatty acid synthase (FASN). Has broad substrate specificity, giving rise to a range of free fatty acids with chain lengths between 10 and 16 carbon atoms (C10 - C16)

More Common Targets

OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P